鎮江德瑞藥物有限公司為南京海辰藥業股份有限公司的全資子公司，注冊資金2200萬, 總投資1.08億。其坐落在鎮江新區國際化學工業園。

鎮江德瑞藥物有限公司作為母公司原料藥生產基地，旨在擴大原料藥的生產規模，更好地開拓海外市場，以實現南京海辰藥業股份有限公司原料藥--制劑產業鏈一體化發展。同時，鎮江德瑞藥物有限公司將以新建原料藥基地為契機，加快推進原料藥品種美國FDA認證、歐盟COS認證等工作，從而實現原料藥產品的海外銷售，為公司發展提供新的經濟增長點。

Zhenjiang Dery Pharmaceutical Co., Ltd is a wholly-owned subsidiary of Nanjing Hicin Pharmaceutical Co., Ltd, with a registered capital of 22 million and a total investment of 108 million. It is located in International Chemical Industrial Park of Zhenjiang New District.

As the API production base of its parent company, Zhenjiang Dery Pharmaceutical Co., Ltd. is aimed at expanding the production capacity of APIs and intermediates, and opening up overseas markets, in order to achieve preparation industry chain integration. At the same time, Zhenjiang Dery Pharmaceutical Co., Ltd. will take the new API base as an opportunity to speed up US FDA certification and EU COS certification of its API products, so as to achieve the overseas sales of API products.